OR14C36

Across TCGA pan-cancer cohorts, OR14C36 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OR14C36 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher OR14C36 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR14C36 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and BRCA are the cancer types where OR14C36 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
UCEC	DFS	Median	All	1.000	0.632	.013	30	view →
BRCA	DFS	Median	All	0.287	0.903	<.001	24	view →
COAD	OS	Median	All	0.476	0.871	<.001	18	view →
LGG	OS	Median	All	0.187	0.909	<.001	12	view →
ESCA	OS	Median	II,III,IV	0.321	0.685	.035	6	view →
SKCM	OS	Median	III,IV	0.289	0.840	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR14C36–ACC (DFS)

Open the ACC breakdown →